-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Insider Buying: The Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Executive Chairman Just Bought 3.5% More Shares
Insider Buying: The Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) Executive Chairman Just Bought 3.5% More Shares
Potential Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) shareholders may wish to note that the Executive Chairman, Yifang Wu, recently bought CN¥887k worth of stock, paying CN¥35.50 for each share. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 3.5%.
See our latest analysis for Shanghai Fosun Pharmaceutical (Group)
The Last 12 Months Of Insider Transactions At Shanghai Fosun Pharmaceutical (Group)
Notably, that recent purchase by Yifang Wu is the biggest insider purchase of Shanghai Fosun Pharmaceutical (Group) shares that we've seen in the last year. So it's clear an insider wanted to buy, even at a higher price than the current share price (being CN¥33.04). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Yifang Wu was the only individual insider to buy during the last year.
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
SHSE:600196 Insider Trading Volume September 15th 2022There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insider Ownership
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Shanghai Fosun Pharmaceutical (Group) insiders own about CN¥73m worth of shares. That equates to 0.09% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
So What Does This Data Suggest About Shanghai Fosun Pharmaceutical (Group) Insiders?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. When combined with notable insider ownership, these factors suggest Shanghai Fosun Pharmaceutical (Group) insiders are well aligned, and that they may think the share price is too low. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. You'd be interested to know, that we found 4 warning signs for Shanghai Fosun Pharmaceutical (Group) and we suggest you have a look.
Of course Shanghai Fosun Pharmaceutical (Group) may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
潛力復星醫藥(集團)股份有限公司(上海證券交易所股票代碼:600196)股東可能會注意到,執行主席吳亦芳最近購買了價值88.7萬元的股票,每股支付35.5元。雖然這對我們來説是一筆非常體面的收購,但從比例上來説,這是一個有點適度的收購,僅使他們的持股增加了3.5%。
請看我們對復星醫藥(集團)的最新分析
復星醫藥集團最近12個月的內幕交易
值得注意的是,吳亦芳最近的收購是我們去年看到的最大規模的復星醫藥(集團)股票內幕收購。因此,很明顯,一名內部人士想要收購,即使是以高於目前股價(33.04元人民幣)的價格。儘管他們的觀點可能在收購後發生了變化,但這至少表明他們對公司的未來充滿信心。在我們看來,內部人士為股票支付的價格非常重要。一般來説,當內部人士以高於當前價格的價格購買股票時,它會吸引我們的眼球,因為這表明他們認為這些股票值得購買,即使是以更高的價格。吳亦芳是去年唯一買入的個人內部人士。
你可以在下面看到過去12個月(由公司和個人)進行的內幕交易的直觀描述。通過點擊下面的圖表,你可以看到每一筆內幕交易的準確細節!
上交所:2022年9月15日內幕交易量600196還有很多其他公司讓內部人士買進股票。你很可能會這麼做不想懷念這一切嗎?免費內部人士正在收購的成長型公司名單。
內部人持股
另一種測試公司領導人與其他股東之間一致性的方法是看他們擁有多少股份。通常,內部人持股越高,內部人就越有可能受到激勵,建立長期的公司。復星醫藥(集團)內部人士持有價值約7300萬元人民幣的股份。這相當於該公司0.09%的股份。雖然這是一個強大但並不突出的內部人持股水平,但這足以表明管理層和小股東之間的某種一致性。
那麼,這些數據對復星醫藥(集團)內部人士有何啟示?
最近的內部收購令人振奮。對過去一年交易的分析也給了我們信心。再加上值得注意的內部人持股,這些因素表明復星醫藥(集團)的內部人很好地結合在一起,他們可能認為股價太低。因此,雖然瞭解內部人士在買入或賣出方面做了什麼是有幫助的,但瞭解一家特定公司面臨的風險也是有幫助的。你會有興趣知道的,我們發現復星醫藥(集團)的4個警示標誌我們建議你去看看。
當然了復星醫藥(集團)可能不是最值得購買的股票。所以你可能想看看這個免費彙集了高質量的公司。
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧